Genuine Monotherapy Approach In EGFRm NSCLC: Analyst Upgrades Switches To Buy On Black Diamond Therapeutics
Tuesday, Black Diamond Therapeutics Inc (NASDAQ: BDTX) announced initial clinical data from the dose escalation portion of Phase 1 clinical study of BDTX-1535 for non-small cell lung cancer (NSCLC)